Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 88Lymphoma, Follicular 50Lymphoma, Non-Hodgkin 36Lymphoma, Large B-Cell, Diffuse 29Lymphoma 29Lymphoma, Mantle-Cell 26Lymphoma, B-Cell, Marginal Zone 22Lymphoma, B-Cell 18Recurrence 12Neoplasms 9Leukemia, B-Cell 6Burkitt Lymphoma 5Waldenstrom Macroglobulinemia 3Neoplasm, Residual 3Leukemia 3Leukemia, Hairy Cell 2Disease 2Tumor Lysis Syndrome 1Part1: Advanced B-cell Malignancies 1Mycosis Fungoides 1Mature B-cell Malignancies 1Mature B-Cell Malignancies 1Lymphoproliferative Disorders 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphatic Diseases 1Leukemia, Prolymphocytic, B-Cell 1Leukemia, Prolymphocytic 1Leukemia, Myeloid, Acute 1Leukemia, Lymphoid 1

Interventions

obinutuzumab 1acalabrutinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Part1: Advanced B-cell Malignancies × obinutuzumab × Lymphoid × Clear all
NCT03198650 2025-10-09

A Phase 1 Study of Acalabrutinib in Japanese Adult Patients With Advanced B-cell Malignancies

AstraZeneca

Phase 1 Active not recruiting
35 enrolled
Lymphoid

Part1: Advanced B-cell Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡